Publications by authors named "J D Hinds"
High-energy nuclear collisions create a quark-gluon plasma, whose initial condition and subsequent expansion vary from event to event, impacting the distribution of the eventwise average transverse momentum [P([p_{T}])]. Disentangling the contributions from fluctuations in the nuclear overlap size (geometrical component) and other sources at a fixed size (intrinsic component) remains a challenge. This problem is addressed by measuring the mean, variance, and skewness of P([p_{T}]) in ^{208}Pb+^{208}Pb and ^{129}Xe+^{129}Xe collisions at sqrt[s_{NN}]=5.
View Article and Find Full Text PDFIntroduction: Given the negative health outcomes of tobacco and cannabis co-use, understanding the co-use of tobacco and cannabis is important, particularly regarding those with higher health burdens, such as sexual minority individuals. This study examined the co-use of tobacco and cannabis by sexual identity.
Methods: The adult sample from the 2022 National Survey on Drug Use and Health (NSDUH) was used for this study.
Article Synopsis
- The study examined pneumococcal disease in internally displaced people (IDP) in Somaliland, revealing a 36% overall carriage rate, with 70% in children under 5.
- Researchers found that 41% of strains carried were from the 10-valent PNEUMOSIL vaccine, potentially causing over half of the invasive diseases.
- The results indicate that implementing pneumococcal conjugate vaccines (PCV) could significantly reduce the disease burden in this vulnerable population.
Background: After pneumococcal disease and colonization have been controlled through vaccination campaigns, a reduced pneumococcal conjugate vaccine (PCV) schedule may be sufficient to sustain that control at reduced costs.
Methods: We investigated whether a single primary dose and booster dose (1p+1) of the 10-valent PCV (PCV10) would be noninferior to alternative dose schedules in sustaining control of carriage of pneumococcal serotypes included in the vaccine. In Nha Trang, Vietnam, an area in which PCV had not been used previously, a PCV10 catch-up campaign was conducted in which the vaccine was offered to children younger than 3 years of age, after which a cluster-randomized trial was conducted in which children received PCV10 at 2, 3, and 4 months of age (3p+0 group); at 2, 4, and 12 months of age (2p+1 group); at 2 and 12 months of age (1p+1 group); or at 12 months of age (0p+1 group).